Charles River Laboratories (CRL) to Acquire Cognate BioServices for $875 Million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Charles River Labs (CRL) PT Raised to $301 at Credit Suisse
February 17, 2021 4:13 PM ESTCredit Suisse analyst Erin Wilson Wright raised the price target on Charles River Labs (NYSE: CRL) to $301.00 (from $259.00) while maintaining a Neutral rating.
The analyst comments "CRLs 4Q EPS ($2.39) handily exceeded our $2.04 on stronger revenues and profitability. Below the line factors also added $0.15. It... More
Charles River Laboratories (CRL) Tops Q4 EPS by 29c, Revenues Beat; Offers FY21 EPS Guidance Above Consensus
February 17, 2021 7:11 AM ESTCharles River Laboratories (NYSE: CRL) reported Q4 EPS of $2.39, $0.29 better than the analyst estimate of $2.10. Revenue for the quarter came in at $791 million versus the consensus estimate of $756.86 million.
Fourth-Quarter Revenue of $791.0 Million and Full-Year Revenue of $2.92 Billion Fourth-Quarter GAAP Earnings per Share of $2.81 and Non-GAAP Earnings per Share of $2.39 Full-Year GAAP Earnings per Share of $7.20 and Non-GAAP Earnings per Share of $8.13 Announces Definitive Agreement to Acquire Cognate BioServices, A Premier, Cell and Gene Therapy CDMOGUIDANCE:
Charles River Laboratories sees FY2021 EPS of... More
